Subscribe
Be the first with the news that moves the market- Algernon Pharmaceuticals (CSE:AGN) completed a feasibility study and has finalized its clinical trial design for a Phase 2 DMT Stroke study
- The work was done through its subsidiary, AGN Neuro, the world’s first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries
- The 40-patient human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke
- Algernon Pharmaceuticals Inc. opened trading at $0.17 per share
Algernon Pharmaceuticals (CSE:AGN) completed a feasibility study and has finalized its clinical trial design for a Phase 2 DMT Stroke study.
The work was done through its subsidiary, AGN Neuro, the world’s first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries.
The 40-patient human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
DMT is a psychedelic substance found in plants and animals, and in the human brain as a neurotransmitter.
The Vancouver-based pharma company’s consultant, Dr. David Nutt, Edmund J. Safra professor of neuropsychopharmacology at Imperial College London, explained in a news release that DMT’s ability to promote neuroplasticity was already demonstrated preclinically, and combined with its neuroprotective effects, it is unique amongst potential therapies being investigated for stroke.
“The potential benefits of DMT in stroke patients not only at the time of their injury, but also in the post-stroke recovery period, makes Algernon’s upcoming trial very, very exciting,” Nutt said.
AGN Neuro is planning to conduct the study at multiple locations in Europe using Algernon’s finished product supply of intravenous DMT. Ethics submission is planned for later in Q3 with the study set to start after approval.
Algernon Pharmaceuticals is a clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease.
Algernon Pharmaceuticals Inc. opened trading at $0.17 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Algernon Pharmaceuticals Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
